As downregulation of JAM-A by miRNA-145 inhibits breast cancer and endometriotic cell invasiveness38, 39, the successful application of the CS–miRNA-145 complexes marks this reagent as a potential candidate for novel antimetastatic therapeutic applications. Here, F11R is linked to breast cancer.